3qge
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | [[Image:3qge. | + | [[Image:3qge.png|left|200px]] |
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_3qge", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_3qge| PDB=3qge | SCENE= }} | {{STRUCTURE_3qge| PDB=3qge | SCENE= }} | ||
===Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide=== | ===Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide=== | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, {{ABSTRACT_PUBMED_21441029}}, adds the Publication Abstract to the page | ||
| - | (as it appears on PubMed at http://www.pubmed.gov), where 21441029 is the PubMed ID number. | ||
| - | --> | ||
{{ABSTRACT_PUBMED_21441029}} | {{ABSTRACT_PUBMED_21441029}} | ||
==About this Structure== | ==About this Structure== | ||
| - | [[3qge]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Hepatitis_c_virus_subtype_1b Hepatitis c virus subtype 1b]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QGE OCA]. | + | [[3qge]] is a 2 chain structure of [[RNA polymerase]] with sequence from [http://en.wikipedia.org/wiki/Hepatitis_c_virus_subtype_1b Hepatitis c virus subtype 1b]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QGE OCA]. |
| + | |||
| + | ==See Also== | ||
| + | *[[RNA polymerase|RNA polymerase]] | ||
==Reference== | ==Reference== | ||
| - | <ref group="xtra">PMID: | + | <ref group="xtra">PMID:021441029</ref><references group="xtra"/> |
[[Category: Hepatitis c virus subtype 1b]] | [[Category: Hepatitis c virus subtype 1b]] | ||
[[Category: RNA-directed RNA polymerase]] | [[Category: RNA-directed RNA polymerase]] | ||
[[Category: Sheriff, S.]] | [[Category: Sheriff, S.]] | ||
| + | [[Category: Finger]] | ||
| + | [[Category: Hcv]] | ||
| + | [[Category: Ns5b]] | ||
| + | [[Category: Palm]] | ||
| + | [[Category: Polymerase]] | ||
| + | [[Category: Thumb]] | ||
| + | [[Category: Transferase-transferase inhibitor complex]] | ||
Revision as of 21:29, 25 July 2012
Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with (2E)-3-(4-{[(1-{[(13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepin-10-yl)carbonyl]amino}cyclopentyl)carbonyl]amino}phenyl)prop-2-enoic acid and (2R)-4-(2,6-dimethoxypyrimidin-4-yl)-N-(4-methoxybenzyl)-1-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperazine-2-carboxamide
Template:ABSTRACT PUBMED 21441029
About this Structure
3qge is a 2 chain structure of RNA polymerase with sequence from Hepatitis c virus subtype 1b. Full crystallographic information is available from OCA.
See Also
Reference
- Gentles RG, Sheriff S, Beno BR, Wan C, Kish K, Ding M, Zheng X, Chupak L, Poss MA, Witmer MR, Morin P, Wang YK, Rigat K, Lemm J, Voss S, Liu M, Pelosi L, Roberts SB, Gao M, Kadow JF. Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2212-5. Epub 2011 Mar 6. PMID:21441029 doi:10.1016/j.bmcl.2011.03.011
